MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences Long Term Debt Current 2011-2026 | GILD
Annual Long Term Debt Current Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | 113 M | 125 M | 111 M | 101 M | 107 M | 99 M | 2.75 B | 2.75 B | - | 983 M | 483 M | 2.7 B | -1.17 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.75 B | -1.17 B | 711 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.81 | 0.15 % | $ 4.42 M | China |
 |
argenx SE
ARGX
|
6.53 M | $ 836.39 | -0.46 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 234.52 | -0.2 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.44 | 3.42 % | $ 8.28 B |  Australia |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
74.5 K | $ 1.24 | -0.8 % | $ 1.83 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
7.23 M | $ 61.58 | -1.66 % | $ 11.7 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Atea Pharmaceuticals
AVIR
|
800 K | $ 4.56 | -1.94 % | $ 384 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Capricor Therapeutics
CAPR
|
749 K | $ 28.24 | 1.18 % | $ 756 M | USA |
 |
Axsome Therapeutics
AXSM
|
434 K | $ 165.14 | -2.83 % | $ 8.22 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
CASI Pharmaceuticals
CASI
|
1.06 M | $ 0.31 | -61.59 % | $ 42.2 M | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 12.21 | -3.48 % | $ 804 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
80.4 M | $ 191.78 | -1.72 % | $ 28.1 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
39.5 M | $ 110.5 | -0.35 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
224 M | $ 14.64 | -0.17 % | $ 4.52 B | USA |